FDA Expands Use of Ivacaftor (Kalydeco) for Cystic FibrosisFDA Expands Use of Ivacaftor (Kalydeco) for Cystic Fibrosis

The agency has approved the CFTR potentiator for use in children aged 6 years and older with cystic fibrosis who have the R117H mutation. FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news